publication . Article . 2016

Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia

Yaseen M. Arabi; Ali H. Hajeer; Thomas C. Luke; Kanakatte Raviprakash; Hanan H. Balkhy; Sameera M. Al Johani; Abdulaziz Al-Dawood; Saad Al-Qahtani; Awad Al-Omari; Fahad Al-Hameed; ...
Open Access English
  • Published: 01 Sep 2016 Journal: Emerging Infectious Diseases, volume 22, issue 9, pages 1,554-1,561 (issn: 1080-6040, eissn: 1080-6059, Copyright policy)
  • Publisher: Centers for Disease Control and Prevention
  • Country: United Kingdom
Abstract
We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trial...
Persistent Identifiers
Subjects
free text keywords: Research, Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia, Middle East respiratory syndrome coronavirus, MERS-CoV, Middle East respiratory syndrome, MERS, intensive care, convalescent phase, convalescent plasma, convalescent-phase plasma, feasibility study, immunotherapy, seroreactive, neutralizing antibodies, antibody titers, viruses, ELISA, microneutralization, indirect immunofluorescent antibody assay, IFA, Saudi Arabia, humans, respiratory infections, high-titer convalescent plasma, Immunotherapy, medicine.medical_treatment, medicine, business.industry, business, Antibody titer, Middle East respiratory syndrome coronavirus, medicine.disease_cause, Virology, Titer, Immunology, Middle East respiratory syndrome, medicine.disease, Intensive care, Antibody, biology.protein, biology, Microneutralization Assay, lcsh:Medicine, lcsh:R, lcsh:Infectious and parasitic diseases, lcsh:RC109-216
32 references, page 1 of 3

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.N Engl J Med. 2012;367:1814–20. 10.1056/NEJMoa1211721 23075143 [OpenAIRE] [PubMed] [DOI]

2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2016 Jun 26]. http://www.who.int/emergencies/mers-cov/en/

3. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015.Osong Public Health Res Perspect. 2015;6:269–78. 10.1016/j.phrp.2015.08.006 26473095 [OpenAIRE] [PubMed] [DOI]

4. Public Health England, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Treatment of MERS-CoV: information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients. V3.0 [cited 2016 Apr 29]. http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/459835/merscov_for_clinicians_sept2015.pdf

5. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.Chest. 2013;144:464–73. 10.1378/chest.12-2907 23450336 [OpenAIRE] [PubMed] [DOI]

6. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects.PLoS Med. 2006;3:e343. 10.1371/journal.pmed.0030343 16968120 [OpenAIRE] [PubMed] [DOI]

7. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.Clin Infect Dis. 2011;52:447–56. 10.1093/cid/ciq106 21248066 [OpenAIRE] [PubMed] [DOI]

8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?Ann Intern Med. 2006;145:599–609. 10.7326/0003-4819-145-8-200610170-00139 16940336 [OpenAIRE] [PubMed] [DOI]

9. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Use of convalescent plasma therapy in SARS patients in Hong Kong.Eur J Clin Microbiol Infect Dis. 2005;24:44–6 .10.1007/s10096-004-1271-9 15 616839 [OpenAIRE] [PubMed] [DOI]

10. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma.Hong Kong Med J. 2006;12:489.17148811 [PubMed]

11. Mair-Jenkins J, Saavedra-Campos M, Baillie K, Cleary P, Khaw FM, Lim WS, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.J Infect Dis. 2015;211:80–90. 10.1093/infdis/jiu396 25030060 [OpenAIRE] [PubMed] [DOI]

12. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection.J Virol. 2015;89:6117–20. 10.1128/JVI.00446-15 25787284 [OpenAIRE] [PubMed] [DOI]

13. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.Springerplus. 2015;4:709. 10.1186/s40064-015-1490-9 26618098 [OpenAIRE] [PubMed] [DOI]

14. Centers for Disease Control and Prevention. CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2015 Sep 22]. http://www.cdc.gov/coronavirus/MERS/lab/lab-testing.html

15. World Health Organization. Laboratory testing for Middle East respiratory syndrome coronavirus: interim recommendations (revised); September 2014 [cited 2015 Sep 22]. http://www.who.int/csr/disease/coronavirus_infections/WHO_interim_recommendations_lab_detection_MERSCoV_092014.pdf

32 references, page 1 of 3
Abstract
We explored the feasibility of collecting convalescent plasma for passive immunotherapy of Middle East respiratory syndrome coronavirus (MERS-CoV) infection by using ELISA to screen serum samples from 443 potential plasma donors: 196 patients with suspected or laboratory-confirmed MERS-CoV infection, 230 healthcare workers, and 17 household contacts exposed to MERS-CoV. ELISA-reactive samples were further tested by indirect fluorescent antibody and microneutralization assays. Of the 443 tested samples, 12 (2.7%) had a reactive ELISA result, and 9 of the 12 had reactive indirect fluorescent antibody and microneutralization assay titers. Undertaking clinical trial...
Persistent Identifiers
Subjects
free text keywords: Research, Feasibility of Using Convalescent Plasma Immunotherapy for MERS-CoV Infection, Saudi Arabia, Middle East respiratory syndrome coronavirus, MERS-CoV, Middle East respiratory syndrome, MERS, intensive care, convalescent phase, convalescent plasma, convalescent-phase plasma, feasibility study, immunotherapy, seroreactive, neutralizing antibodies, antibody titers, viruses, ELISA, microneutralization, indirect immunofluorescent antibody assay, IFA, Saudi Arabia, humans, respiratory infections, high-titer convalescent plasma, Immunotherapy, medicine.medical_treatment, medicine, business.industry, business, Antibody titer, Middle East respiratory syndrome coronavirus, medicine.disease_cause, Virology, Titer, Immunology, Middle East respiratory syndrome, medicine.disease, Intensive care, Antibody, biology.protein, biology, Microneutralization Assay, lcsh:Medicine, lcsh:R, lcsh:Infectious and parasitic diseases, lcsh:RC109-216
32 references, page 1 of 3

1. Zaki AM, van Boheemen S, Bestebroer TM, Osterhaus AD, Fouchier RA. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia.N Engl J Med. 2012;367:1814–20. 10.1056/NEJMoa1211721 23075143 [OpenAIRE] [PubMed] [DOI]

2. World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2016 Jun 26]. http://www.who.int/emergencies/mers-cov/en/

3. Korea Centers for Disease Control and Prevention. Middle East respiratory syndrome coronavirus outbreak in the Republic of Korea, 2015.Osong Public Health Res Perspect. 2015;6:269–78. 10.1016/j.phrp.2015.08.006 26473095 [OpenAIRE] [PubMed] [DOI]

4. Public Health England, International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC). Treatment of MERS-CoV: information for clinicians. Clinical decision-making support for treatment of MERS-CoV patients. V3.0 [cited 2016 Apr 29]. http://www.gov.uk/government/uploads/system/uploads/attachment_data/file/459835/merscov_for_clinicians_sept2015.pdf

5. Hung IF, To KK, Lee CK, Lee KL, Yan WW, Chan K, Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection.Chest. 2013;144:464–73. 10.1378/chest.12-2907 23450336 [OpenAIRE] [PubMed] [DOI]

6. Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects.PLoS Med. 2006;3:e343. 10.1371/journal.pmed.0030343 16968120 [OpenAIRE] [PubMed] [DOI]

7. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection.Clin Infect Dis. 2011;52:447–56. 10.1093/cid/ciq106 21248066 [OpenAIRE] [PubMed] [DOI]

8. Luke TC, Kilbane EM, Jackson JL, Hoffman SL. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?Ann Intern Med. 2006;145:599–609. 10.7326/0003-4819-145-8-200610170-00139 16940336 [OpenAIRE] [PubMed] [DOI]

9. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Use of convalescent plasma therapy in SARS patients in Hong Kong.Eur J Clin Microbiol Infect Dis. 2005;24:44–6 .10.1007/s10096-004-1271-9 15 616839 [OpenAIRE] [PubMed] [DOI]

10. Kong LK, Zhou BP. Successful treatment of avian influenza with convalescent plasma.Hong Kong Med J. 2006;12:489.17148811 [PubMed]

11. Mair-Jenkins J, Saavedra-Campos M, Baillie K, Cleary P, Khaw FM, Lim WS, The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis.J Infect Dis. 2015;211:80–90. 10.1093/infdis/jiu396 25030060 [OpenAIRE] [PubMed] [DOI]

12. Zhao J, Perera RA, Kayali G, Meyerholz D, Perlman S, Peiris M. Passive immunotherapy with dromedary immune serum in an experimental animal model for Middle East respiratory syndrome coronavirus infection.J Virol. 2015;89:6117–20. 10.1128/JVI.00446-15 25787284 [OpenAIRE] [PubMed] [DOI]

13. Arabi Y, Balkhy H, Hajeer AH, Bouchama A, Hayden FG, Al-Omari A, Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol.Springerplus. 2015;4:709. 10.1186/s40064-015-1490-9 26618098 [OpenAIRE] [PubMed] [DOI]

14. Centers for Disease Control and Prevention. CDC laboratory testing for Middle East respiratory syndrome coronavirus (MERS-CoV) [cited 2015 Sep 22]. http://www.cdc.gov/coronavirus/MERS/lab/lab-testing.html

15. World Health Organization. Laboratory testing for Middle East respiratory syndrome coronavirus: interim recommendations (revised); September 2014 [cited 2015 Sep 22]. http://www.who.int/csr/disease/coronavirus_infections/WHO_interim_recommendations_lab_detection_MERSCoV_092014.pdf

32 references, page 1 of 3
Any information missing or wrong?Report an Issue